News
Obesity Drugmaker Novo Nordisk Plunges as It Cuts Forecasts Again
Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its operating profit growth forecast to 10%-16%, from a prior outlook of 16-24%. (Reporting by Stine Jacobsen, editing by Terje Solsvik and Essi Lehto)
Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.
(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than ...
Shares in the $247 bln obesity drugmaker fell over 20% after it said sales would grow more slowly than expected. Competition ...
Novo Nordisk NOVO.B 1.19% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss ...
Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy.
Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health, pushing Hims shares down 31% in morning trading.
On April 29, Novo Nordisk (NVO 1.02%) and Hims & Hers Health (HIMS -5.46%) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy.
Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth ...
Danish pharmaceutical giant Novo Nordisk on Tuesday cuts its full-year sales and profit guidance, citing weaker growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback